Dutch biotech company Pepscope is establishing a laboratory in Wageningen. Pepscope develops a technology to improve so-called kinase inhibitors, which are small molecules that deactivate specific proteins. Kinase inhibitors are a group of targeted drugs that are effective against cancer types in select groups of patients. Oost NL previously provided funding to the company from ION+-fund and as of July 2021 Pepscope is partly located in Wageningen.

Pepscope has reached an agreement with Kadans and rents a space in the BioPartner Centre Wageningen. Oost NL supported Pepscope in finding a suitable place in Gelderland. Eventually, a space in Wageningen became available that corresponded well with the company’s wishes. In the coming years, Pepscope expects to work on its QuantaKinome™ technology at this location, while its headquarters will remain in Utrecht.

Anna Ressa, CEO and co-founder of Pepscope: “This location in Wageningen is a great step for us. Finding suitable lab space is not easy, but with help from Oost NL we managed to find a location. In Wageningen we will start our new commercial phase. This facility will now double our efforts to provide a trustworthy service for our clients. We are actively working on improving our technology more and more with our partners.”

Rik Luimes, project manager Health at Oost NL: “Finding suitable lab space is a challenge these days but we are not running away from that. With this location, Pepscope takes the next step in its ambition to support the selection of optimal therapies for individual patients. A valuable addition to the dynamic life sciences ecosystem in the east of the Netherlands.”